The Chemours Company

Second Quarter Earnings Presentation

August 3, 2017

Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words “believe,” “expect,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date the statements were made. These forward-looking statements address, among other things, our agreement with DuPont relating to the MDL Settlement, the outcome or resolution of any pending or future environmental liabilities, litigation and other legal proceedings or contingencies, anticipated future operating and financial performance, business plans and prospects, transformation plans, cost savings targets, plans to increase profitability and our outlook for Adjusted EBITDA and free cash flow that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours’ control. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include: whether the MDL Settlement becomes effective; the outcome of any pending or future litigation related to PFOA; the performance by DuPont of its obligations under the MDL Settlement; the terms of any final agreement between Chemours and DuPont relating to the MDL Settlement; and other risks, uncertainties and other factors discussed in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2016. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

This presentation contains certain supplemental measures of performance that are not required by, or presented in accordance with, generally accepted accounting principles in the United States (“GAAP”). These Non-GAAP measures include Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA margin, and Free Cash Flow, which should not be considered as replacements of GAAP. Free Cash Flow is defined as Cash from Operations minus cash used for PP&E purchases. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income (Loss), Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA margin and Free Cash Flow to evaluate the Company’s performance excluding the impact of certain non-cash charges and other special items in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Additional information for investors is available on the company’s website at investors.chemours.com.

Second Quarter 2017 Highlights

Significant year-over-year improvements across all key financial metrics

Double-digit TiO_2 sales improvement driven by price actions & increased demand

Strong demand for Opteon™ refrigerants and entire fluoropolymers portfolio

Increased FY2017 outlook based on anticipated strong business performance

Chemours™

2Q17 Overview

($ in millions, except for share amounts, unless otherwise noted)

Second Quarter Financial Summary

	2Q17	2Q16	Δ Yr/Yr
Net Sales	$1,588	$1,383	$205
Net Income (loss)[1]	161	(18)	179
Adj. Net Income	166	49	117
EPS[2]	$0.84	($0.10)	$0.94
Adj. EPS[2]	$0.87	$0.27	$0.60
Adj. EBITDA	361	187	174
Adj. EBITDA Margin (%) [3]	23	14	9
Free Cash Flow[4]	114	11	103
Pre-Tax ROIC[5]	27	9	18

Year-Over-Year

- Results primarily driven by increased sales of Ti-Pure™ titanium dioxide and Opteon™ refrigerants
- Adjusted EBITDA margin improvement of 900 basis points primarily from higher prices and volumes
- Free Cash Flow of $114M improved by $103M including working capital use of $83M, consistent with normal seasonal trends
- Continued expansion in Pre-Tax ROIC

[1] Net Income attributable to Chemours
[2] Calculation based on diluted share count
[3] Defined as Adjusted EBITDA divided by Net Sales
[4] Defined as Cash from Operations minus cash used for PP&E purchases
[5] Defined as Adjusted EBITDA less depreciation & amortization divided by invested capital
See reconciliation of non-GAAP measures in the Appendix

Chemours™

Adjusted EBITDA Bridge: 2Q17 versus 2Q16



Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Liquidity Position

($ in millions)



- Free Cash Flow of $114M versus $11M in 2Q16[1]
- Working capital build reflects volume, price, and seasonality impacts
- Successfully completed $500M bond issuance in 2Q17
- Total Liquidity of ~$2.2B, including revolver availability of $750M[2]
- Net debt of $2.5B, net leverage ratio[3] of ~2.2 times on a trailing twelve month basis

[1] Includes cash restructuring payments of $14 million in 2Q17
[2] Includes as of 6/30/17, Chemours had $104M in Letters of credit outstanding
[3] Senior Secured Net Debt/EBITDA is 1.2x based on Credit Agreement definition
* Net Income attributable to Chemours
**Includes net proceeds of $489 million from debt issuance on May 23, 2017

Chemours™

Titanium Technologies Business Summary

Second Quarter Highlights

- Strong volumes as a result of customer preference for high-quality Ti-Pure™ titanium dioxide across all regions and applications
- Price increases based on applications, grades, and end users communicated through customer letters
- Manufacturing facilities continue to run at full utilization to meet customer demand

Outlook Commentary

- Full-year volume growth expected to be high single-digits
- Working with customers to implement recently communicated price increases
- Introducing additional TiO_2 grades at Altamira to support value-based offerings; expected to reach full capability in 2018

Financial Summary *($ millions)*

	2Q17	2Q16	Δ Yr/Yr
Sales	$729	$596	$133
Adjusted EBITDA	$193	$111	$82
Adjusted EBITDA Margin (%)	*26*	*19*	*7*

Sales Drivers

	Yr/Yr % Δ
Price[1]	15
Currency	(1)
Volume[1]	8

[1] TiO_2 global average price was up 14%, excluding other minor product revenue

Chemours™

See Segment Net Sales and Adjusted EBITDA measures in the Appendix

Fluoroproducts Business Summary

Second Quarter Highlights

- Opteon™ refrigerant revenue doubled versus previous year
- Higher base refrigerant prices as a result of current supply tightness and regulatory enforcement in Europe and the U.S.
- Fluoropolymers double-digit volume growth offsetting moderating pricing headwinds

Outlook Commentary

- Demand for Opteon™ refrigerants expected to remain a strong source of growth driven by regulations and economic incentives
- Opteon™ Corpus Christi expansion on track
- Base refrigerants expected to benefit from favorable regulatory environment
- Continuing fluoropolymer broad market penetration in industrial applications

Financial Summary *($ millions)*

	2Q17	2Q16	Δ Yr/Yr
Sales	$710	$573	$137
Adjusted EBITDA	$197	$105	$92
Adjusted EBITDA Margin (%)	*28*	*18*	*10*

Sales Drivers

	Yr/Yr % Δ
Price	1
Currency	(0)
Volume	23

Chemours™

See Segment Net Sales and Adjusted EBITDA measures in the Appendix

Chemical Solutions Business Summary

Second Quarter Highlights

- Continued impact on sales and Adjusted EBITDA from 2016 divestitures and site closure
- Strong volume increase due to higher demand for performance chemicals & intermediates and mining solutions products
- Increased raw material costs partially mitigated by price increases

Outlook Commentary

- Expected volume growth in mining solutions driven by North American gold production demand with some near-term price pressure
- Performance chemicals & intermediates product lines at Belle, WV expected to be modestly positive for 2017
- New mining solutions manufacturing facility construction underway; expect completion by end of 2018

Financial Summary *($ millions)*

	2Q17	2Q16	Δ Yr/Yr
Sales	$149	$214	($65)
Adjusted EBITDA	$7	$11	($4)
Adjusted EBITDA Margin (%)	*5*	*5*	*0*

Sales Drivers

	Yr/Yr % Δ
Price	1
Currency	0
Volume	9
Portfolio	(40)

Chemours™

See Segment Net Sales and Adjusted EBITDA measures in the Appendix

2017 Outlook

2017 Adjusted EBITDA Expected To Be Between $1.3 - $1.4 Billion With Approximately Breakeven Free Cash Flow, Including Payment Of PFOA MDL Settlement

Key Factors Influencing Market Performance

Market Factors

- TiO_2 price
- Currency
- End-market demand
- Seasonality
- Regulatory uncertainty

Chemours Initiatives

- Cost reductions
- Altamira expansion ramp-up
- Opteon™ market adoption
- Corpus Christi expansion
- Impacts from divestitures

Chemours™

See reconciliation of estimated Adjusted EBITDA in Appendix

Appendix

GAAP Net Income (Loss) to Adjusted Net Income and Adjusted EBITDA Reconciliations

GAAP Net Income (Loss) to Adjusted Net Income and Adjusted EBITDA Tabular Reconciliations

($ in millions except per share amounts)	Three months ended June 30, 2017 $ amounts	Three months ended June 30, 2017 $ per share	Three months ended June 30, 2016 $ amounts	Three months ended June 30, 2016 $ per share	Three months ended March 31, 2017 $ amounts	Three months ended March 31, 2017 $ per share
Net income (loss) attributable to Chemours	$ 161	$ 0.87	$ (18)	$ (0.10)	$ 150	$ 0.82
Non-operating pension and other post-retirement employee benefit income	(10)	(0.05)	(7)	(0.04)	(8)	(0.04)
Exchange (gains) losses	(2)	(0.01)	14	0.08	(5)	(0.03)
Restructuring charges	6	0.03	9	0.05	12	0.07
Asset-related charges	2	0.01	63	0.35	-	-
Loss (gain) on sale of assets or businesses	2	0.01	1	0.01	(16)	(0.09)
Transaction costs	2	0.01	12	0.07	-	-
Legal and other charges	10	0.05	13	0.07	7	0.04
(Benefit from) provision for income taxes relating to reconciling items [1]	(5)	(0.03)	(38)	(0.21)	2	0.01
Adjusted Net Income [3]	$ 166	$ 0.90	$ 49	$ 0.27	$ 142	$ 0.77
Net income attributable to non-controlling interests	-		-		1	
Interest expense	55		50		51	
Depreciation and amortization	71		73		71	
All remaining provision for income taxes [1]	69		15		20	
Adjusted EBITDA	$ 361		$ 187		$ 285	
Weighted average number of common shares outstanding - basic	185,069,436		181,477,672		183,408,309	
Weighted average number of common shares outstanding - diluted	191,126,639		181,477,672		189,149,930	
Earnings (loss) per share - basic	$ 0.87		$ (0.10)		$ 0.82	
Earnings (loss) per share - diluted [2]	$ 0.84		$ (0.10)		$ 0.79	
Adjusted earnings per share - basic	$ 0.90		$ 0.27		$ 0.77	
Adjusted earnings per share - diluted [2]	$ 0.87		$ 0.27		$ 0.75	

[1] Total of provision for (benefit from) income taxes reconciles to the amount reported in the Consolidated Statements of Operations for the three months ended June 30, 2017 and 2016, and for the three months ended March 31, 2017.

[2] Diluted earnings (loss) per share is calculated using net income (loss) available to common shareholders divided by diluted w eighted-average shares of common shares outstanding during each period, w hich includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in w hich there is a loss because the inclusion of the potential common shares w ould have an anti-dilutive effect.

[3] Immaterial differences may exist in summation of per share amounts due to rounding.

Chemours™

Free Cash Flow Reconciliation

GAAP Cash Flow to Free Cash Flow Tabular Reconciliations

($ in millions unless otherwise noted)	Three months ended			Six months ended	
	June 30,		March 31,	June 30,	
	2017	2016	2017	2017	2016
Cash flows provided by operating activities [1]	$ 183	$ 90	$ 41	$ 224	$ 126
Cash flows used for purchases of property, plant and equipment	(69)	(79)	(69)	(138)	(168)
Free cash flows	$ 114	$ 11	$ (28)	$ 86	$ (42)

[1] Cash flows from operating activities for the six months ended June 30, 2017 and 2016 include the DuPont prepayment of $190 million received in the first quarter of 2016, of which $0 million and $131 million remain outstanding as of June 30, 2017 and 2016, respectively. Excluding the DuPont prepayment, free cash flows for the six months ended June 30, 2016 would have been negative $173 million.

Chemours™

Segment Net Sales and Adjusted EBITDA (unaudited)

SEGMENT NET SALES AND ADJUSTED EBITDA (UNAUDITED)

($ in millions unless otherwise noted)

	Three months ended June 30, 2017	Three months ended June 30, 2016	Three months ended March 31, 2017
SEGMENT NET SALES			
Titanium Technologies	$ 729	$ 596	$ 646
Fluoroproducts	710	573	652
Chemical Solutions	149	214	139
Total Company	$ 1,588	$ 1,383	$ 1,437
SEGMENT ADJUSTED EBITDA			
Titanium Technologies	$ 193	$ 111	$ 159
Fluoroproducts	197	105	155
Chemical Solutions	7	11	12
Corporate & Other	(36)	(40)	(41)
Total Company	$ 361	$ 187	$ 285
SEGMENT ADJUSTED EBITDA MARGIN			
Titanium Technologies	26.5%	18.6%	24.6%
Fluoroproducts	27.7%	18.3%	23.8%
Chemical Solutions	4.7%	5.1%	8.6%
Corporate & Other	0.0%	0.0%	0.0%
Total Company	22.7%	13.5%	19.8%

Chemours™

See reconciliation of Non-GAAP measures in the Appendix

Reconciliation of Outlook

2017 Estimated GAAP Net Income to Estimated Adjusted EBITDA Tabular Reconciliation

(UNAUDITED)

($ in millions unless otherwise noted)

Estimated Net Income [1]	$605 - 680
Provision for income taxes [1 2]	195 - 220
Interest expense, net	~ 220
Depreciation and amortization	~ 280
Other reconciling items [1 3]	~ (0)
Estimated Adjusted EBITDA [1]	$1,300 - 1,400

[1] Our estimates reflect our current visibility and expectations of market factors, such as but not limited to, currency movements, TiO2 prices and end-market demand. Actual results could differ materially from the current estimates due to market factors and unknown or uncertainty of other factors, such as an estimate of non-operating pension benefit costs with respect to our foreign pension plans including settlements or curtailments, cost savings actions that may be taken in the future, the impact of currency movements on our results including exchange gains and losses and the related tax effects.

[2] Provisions for income tax is based on our current estimate of geographic mix of earnings and does not include potential tax effect of future discrete items.

[3] Includes non-operating pension benefit income, exchange gains and losses, gain on sale of assets, restructuring and other charges recognized in the first half of 2017.

Chemours™

Chemours™